Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

Anticoagulation Treatment in Venous Thromboembolism: Options and Optimal Duration

Author(s): Stavrianna Diavati , Marios Sagris, Dimitrios Terentes-Printzios* and Charalambos Vlachopoulos

Volume 28, Issue 4, 2022

Published on: 16 December, 2021

Page: [296 - 305] Pages: 10

DOI: 10.2174/1381612827666211111150705

Price: $65

Abstract

Venous thromboembolism (VTE), clinically presented as deep-vein thrombosis (DVT) or pulmonary embolism (PE), constitutes a major global healthcare concern with severe complications, long-term morbidity, and mortality. Although several clinical, genetic, and acquired risk factors for VTE have been identified, the molecular pathophysiology and mechanisms of disease progression remain poorly understood. Anticoagulation has been the cornerstone of therapy for decades, but data is sparse regarding primary and secondary VTE prevention, as well as optimal therapy duration. In this review, we discuss the role of factor Xa in the coagulation cascade and the different choices of anticoagulation therapy based on patients’ predisposing risk factors and risk of event recurrence. Further, we compare newer agents to traditional anticoagulation treatment based on the most recent studies and guidelines.

Keywords: Venous thromboembolism, deep vein thrombosis, pulmonary embolism, treatment options, duration, direct oral anticoagulants

« Previous Next »
[1]
15th Stearing Committee for World Thrombosis Day ISCfWT. . Thrombosis: a major contributor to global disease burden. Thromb Res 2014; 134(5): 931-8.
[http://dx.doi.org/10.1016/j.thromres.2014.08.014] [PMID: 25312343]
[2]
Sagris M, Antonopoulos AS, Theofilis P, et al. Risk factors profile of young and older patients with Myocardial Infarction. Cardiovasc Res 2021; cvab264.
[http://dx.doi.org/10.1093/cvr/cvab264] [PMID: 34358302]
[3]
Cohen AT, Agnelli G, Anderson FA, et al. VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98(4): 756-64.
[PMID: 17938798]
[4]
Cohen AT, Imfeld S, Rider T. Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results. Adv Ther 2014; 31(5): 473-93.
[http://dx.doi.org/10.1007/s12325-014-0119-7] [PMID: 24821599]
[5]
Beyer-Westendorf J, Ageno W. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. Thromb Haemost 2015; 113(2): 231-46.
[http://dx.doi.org/10.1160/TH14-06-0484] [PMID: 25319150]
[6]
Ten Cate V, Koeck T, Panova-Noeva M, et al. A prospective cohort study to identify and evaluate endotypes of venous thromboembolism: Rationale and design of the Genotyping and Molecular Phenotyping in Venous ThromboEmbolism project (GMP-VTE). Thromb Res 2019; 181: 84-91.
[http://dx.doi.org/10.1016/j.thromres.2019.07.019] [PMID: 31374513]
[7]
Aleva FE, Voets LWLM, Simons SO, et al. Prevalence and localization of pulmonary embolism in unexplained acute exacerbations of COPD: A systematic review and meta-analysis. Chest 2017; 151(3): 544-54.
[http://dx.doi.org/10.1016/j.chest.2016.07.034] [PMID: 27522956]
[8]
Sagris M, Theofilis P, Antonopoulos AS, et al. Inflammatory mechanisms in COVID-19 and atherosclerosis: current pharmaceutical perspectives. Int J Mol Sci 2021; 22(12): 6607.
[http://dx.doi.org/10.3390/ijms22126607] [PMID: 34205487]
[9]
Theofilis P, Sagris M, Oikonomou E, et al. Inflammatory mechanisms contributing to endothelial dysfunction. Biomedicines 2021; 9(7): 781.
[http://dx.doi.org/10.3390/biomedicines9070781] [PMID: 34356845]
[10]
Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost 2016; 14(7): 1480-3.
[http://dx.doi.org/10.1111/jth.13336] [PMID: 27428935]
[11]
Aboyans V, Brodmann M, De Carlo M, et al. The year in cardiology 2014: peripheral circulation. Eur Heart J 2015; 36(10): 591-7.
[http://dx.doi.org/10.1093/eurheartj/ehu515] [PMID: 25559131]
[12]
Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4(19): 4693-738.
[http://dx.doi.org/10.1182/bloodadvances.2020001830] [PMID: 33007077]
[13]
Mazzolai L, Aboyans V, Ageno W, et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J 2018; 39(47): 4208-18.
[http://dx.doi.org/10.1093/eurheartj/ehx003] [PMID: 28329262]
[14]
Goldhaber SZ. Risk factors for venous thromboembolism. J Am Coll Cardiol 2010; 56(1): 1-7.
[http://dx.doi.org/10.1016/j.jacc.2010.01.057] [PMID: 20620709]
[15]
Albertsen IE, Nielsen PB, Søgaard M, et al. Risk of recurrent venous thromboembolism: a danish nationwide cohort study. Am J Med 2018; 131(9): 1067-1074.e4.
[http://dx.doi.org/10.1016/j.amjmed.2018.04.042] [PMID: 30266273]
[16]
Kearon C, Parpia S, Spencer FA, et al. Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort study. J Thromb Haemost 2019; 17(7): 1144-52.
[http://dx.doi.org/10.1111/jth.14458] [PMID: 31033194]
[17]
Hotoleanu C. Genetic risk factors in venous thromboembolism. Adv Exp Med Biol 2017; 906: 253-72.
[http://dx.doi.org/10.1007/5584_2016_120] [PMID: 27638626]
[18]
Kakkos SK, Kirkilesis GI, Tsolakis IA. Editor’s Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc Surg 2014; 48(5): 565-75.
[http://dx.doi.org/10.1016/j.ejvs.2014.05.001] [PMID: 24951377]
[19]
Cushman M. Inherited risk factors for venous thrombosis. Hematology (Am Soc Hematol Educ Program) 2005; 2005(1): 452-7.
[http://dx.doi.org/10.1182/asheducation-2005.1.452] [PMID: 16304419]
[20]
Agrifoglio G, Edwards EA. Venous stasis after ligation of femoral veins or inferior vena cava. JAMA 1961; 178: 1-7.
[http://dx.doi.org/10.1001/jama.1961.03040400003001] [PMID: 13859663]
[21]
Frisoli JK, Sze D. Mechanical thrombectomy for the treatment of lower extremity deep vein thrombosis. Tech Vasc Interv Radiol 2003; 6(1): 49-52.
[http://dx.doi.org/10.1053/tvir.2003.36439] [PMID: 12772129]
[22]
Augustinos P, Ouriel K. Invasive approaches to treatment of venous thromboembolism. Circulation 2004; 110(9)(Suppl. 1): I27-34.
[http://dx.doi.org/10.1161/01.CIR.0000140900.64198.f4] [PMID: 15339878]
[23]
Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: pp. (6 Suppl): 454S-545S.
[24]
Meissner MH, Gloviczki P, Comerota AJ, et al. Early thrombus removal strategies for acute deep venous thrombosis: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg 2012; 55(5): 1449-62.
[http://dx.doi.org/10.1016/j.jvs.2011.12.081] [PMID: 22469503]
[25]
Ochoa Chaar CI, Aurshina A. Endovascular and open surgery for deep vein thrombosis. Clin Chest Med 2018; 39(3): 631-44.
[http://dx.doi.org/10.1016/j.ccm.2018.04.014] [PMID: 30122186]
[26]
Mastoris I, Kokkinidis DG, Bikakis I, et al. Catheter-directed thrombolysis vs. anticoagulation for the prevention and treatment of post-thrombotic syndrome in deep vein thrombosis: An updated systematic review and meta-analysis of randomized trials. Phlebology 2019; 34(10): 675-82.
[http://dx.doi.org/10.1177/0268355519835618] [PMID: 30871438]
[27]
Sudheendra D, Vedantham S. Catheter-directed therapy options for iliofemoral venous thrombosis. Surg Clin North Am 2018; 98(2): 255-65.
[http://dx.doi.org/10.1016/j.suc.2017.11.012] [PMID: 29502770]
[28]
Fleck D, Albadawi H, Shamoun F, Knuttinen G, Naidu S, Oklu R. Catheter-directed thrombolysis of deep vein thrombosis: literature review and practice considerations. Cardiovasc Diagn Ther 2017; 7(Suppl. 3): S228-37.
[http://dx.doi.org/10.21037/cdt.2017.09.15] [PMID: 29399526]
[29]
Sista AK, Vedantham S, Kaufman JA, Madoff DC. Endovascular interventions for acute and chronic lower extremity deep venous disease: state of the art. Radiology 2015; 276(1): 31-53.
[http://dx.doi.org/10.1148/radiol.2015132603] [PMID: 26101920]
[30]
O’Connor P, Lookstein R. Endovascular interventions for venous disease. Tech Vasc Interv Radiol 2018; 21(2): 55-64.
[http://dx.doi.org/10.1053/j.tvir.2018.03.010] [PMID: 29784123]
[31]
Kahn SR, Julian JA, Kearon C, et al. Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. J Vasc Surg Venous Lymphat Disord 2020; 8(1): 8-23.e18.
[http://dx.doi.org/10.1016/j.jvsv.2019.03.023] [PMID: 31843251]
[32]
Lim GB. Thrombosis: Pharmacomechanical thrombolysis in DVT. Nat Rev Cardiol 2018; 15(2): 68.
[PMID: 29263448]
[33]
Weinberg I, Vedantham S, Salter A, et al. Relationships between the use of pharmacomechanical catheter-directed thrombolysis, sonographic findings, and clinical outcomes in patients with acute proximal DVT: Results from the ATTRACT Multicenter Randomized Trial. Vasc Med 2019; 24(5): 442-51.
[http://dx.doi.org/10.1177/1358863X19862043] [PMID: 31354089]
[34]
Robertson L, McBride O, Burdess A. Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis. Cochrane Database Syst Rev 2016; 11: CD011536.
[http://dx.doi.org/10.1002/14651858.CD011536.pub2] [PMID: 27814432]
[35]
Vedantham S, Thorpe PE, Cardella JF, et al. Quality improvement guidelines for the treatment of lower extremity deep vein thrombosis with use of endovascular thrombus removal. J Vasc Interv Radiol 2009; 20(7)(Suppl.): S227-39.
[http://dx.doi.org/10.1016/j.jvir.2009.04.016] [PMID: 19560003]
[36]
Chan NC, Eikelboom JW, Weitz JI. Evolving treatments for arterial and venous thrombosis: role of the direct oral anticoagulants. Circ Res 2016; 118(9): 1409-24.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.306925] [PMID: 27126650]
[37]
Siasos G, Skotsimara G, Oikonomou E, et al. Antithrombotic treatment in diabetes mellitus: a review of the literature about antiplatelet and anticoagulation strategies used for diabetic patients in primary and secondary prevention. Curr Pharm Des 2020; 26(23): 2780-8.
[http://dx.doi.org/10.2174/1381612826666200417145605] [PMID: 32303164]
[38]
Renner E, Barnes GD. Antithrombotic management of venous thromboembolism: JACC focus seminar. J Am Coll Cardiol 2020; 76(18): 2142-54.
[http://dx.doi.org/10.1016/j.jacc.2020.07.070] [PMID: 33121722]
[39]
Bauer KA. Pros and cons of new oral anticoagulants. Hematology (Am Soc Hematol Educ Program) 2013; 2013: 464-70.
[http://dx.doi.org/10.1182/asheducation-2013.1.464] [PMID: 24319220]
[40]
Sagris M, Kokkinidis DG, Lempesis IG, et al. Nutrition, dietary habits, and weight management to prevent and treat patients with peripheral artery disease. Rev Cardiovasc Med 2020; 21(4): 565-75.
[http://dx.doi.org/10.31083/j.rcm.2020.04.202] [PMID: 33388001]
[41]
Chopard R, Albertsen IE, Piazza G. Diagnosis and treatment of lower extremity venous thromboembolism: a review. JAMA 2020; 324(17): 1765-76.
[http://dx.doi.org/10.1001/jama.2020.17272] [PMID: 33141212]
[42]
Pokorney SD, Holmes DN, Thomas L, et al. Association between warfarin control metrics and atrial fibrillation outcomes in the outcomes registry for better informed treatment of atrial fibrillation. JAMA Cardiol 2019; 4(8): 756-64.
[http://dx.doi.org/10.1001/jamacardio.2019.1960] [PMID: 31268487]
[43]
Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018; 39(9): 763-816.
[http://dx.doi.org/10.1093/eurheartj/ehx095] [PMID: 28886620]
[44]
Sagris M, Giannopoulos S, Giannopoulos S, et al. Transcervical carotid artery revascularization: A systematic review and meta-analysis of outcomes. J Vasc Surg 2021; 74(2): 657-665.e12.
[http://dx.doi.org/10.1016/j.jvs.2021.03.032] [PMID: 33864829]
[45]
Posch F, Königsbrügge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 2015; 136(3): 582-9.
[http://dx.doi.org/10.1016/j.thromres.2015.07.011] [PMID: 26210891]
[46]
Ansell J. New anticoagulants and their potential impact on the treatment of thromboembolic disease. Curr Hematol Rep 2004; 3(5): 357-62.
[PMID: 15341703]
[47]
Camire RM. Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics. J Thromb Thrombolysis 2021; 52(2): 383-90.
[http://dx.doi.org/10.1007/s11239-021-02456-w] [PMID: 33886037]
[48]
Harder S, Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol 2013; 69(9): 1617-33.
[http://dx.doi.org/10.1007/s00228-013-1510-z] [PMID: 23619611]
[49]
Sindet-Pedersen C, Pallisgaard JL, Staerk L, et al. Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study. Sci Rep 2017; 7(1): 3347.
[http://dx.doi.org/10.1038/s41598-017-03596-x] [PMID: 28611403]
[50]
Kopytek M, Zabczyk M, Natorska J, Malinowski KP, Undas A. Effects of direct oral anticoagulants on thromboelastographic parameters and fibrin clot properties in patients with venous thromboembolism. J Physiol Pharmacol 2020; 71(1)
[PMID: 32350148]
[51]
Chan NC, Bhagirath V, Eikelboom JW. Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag 2015; 11: 343-51.
[PMID: 26170684]
[52]
Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended thromboprophylaxis with betrixaban in acutely Ill medical patients. N Engl J Med 2016; 375(6): 534-44.
[http://dx.doi.org/10.1056/NEJMoa1601747] [PMID: 27232649]
[53]
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart rhythm society. J Am Coll Cardiol 2019; 74(1): 104-32.
[http://dx.doi.org/10.1016/j.jacc.2019.01.011] [PMID: 30703431]
[54]
Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008; 99(1): 208-14.
[http://dx.doi.org/10.1160/TH07-04-0252] [PMID: 18217156]
[55]
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation 2019; 140(2): e125-51.
[http://dx.doi.org/10.1161/CIR.0000000000000665] [PMID: 30686041]
[56]
Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141: p. (2 Suppl): e152S-84S.
[57]
Zhang Y, Zhang M, Tan L, Pan N, Zhang L. The clinical use of Fondaparinux: A synthetic heparin pentasaccharide. Prog Mol Biol Transl Sci 2019; 163: 41-53.
[http://dx.doi.org/10.1016/bs.pmbts.2019.02.004] [PMID: 31030756]
[58]
Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest . 2012; 141(2 Suppl): e419S-96S.
[59]
Othieno R, Okpo E, Forster R. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev 2018; 1: CD003076.
[http://dx.doi.org/10.1002/14651858.CD003076.pub3] [PMID: 29315455]
[60]
Vinson DR, Mark DG, Chettipally UK, et al. Increasing safe outpatient management of emergency department patients with pulmonary embolism: a controlled pragmatic trial. Ann Intern Med 2018; 169(12): 855-65.
[http://dx.doi.org/10.7326/M18-1206] [PMID: 30422263]
[61]
Peppas S, Sagris Μ, Bikakis I, et al. A systematic review and meta-analysis on the efficacy and safety of direct oral anticoagulants in patients with peripheral artery disease. Ann Vasc Surg 2021; S0890-5096(21)00674-9.
[PMID: 34644644]
[62]
Kakkos SK, Gohel M, Baekgaard N, et al. Editor’s Choice - European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg 2021; 61(1): 9-82.
[http://dx.doi.org/10.1016/j.ejvs.2020.09.023] [PMID: 33334670]
[63]
Aboyans V, Björck M, Brodmann M, et al. Questions and answers on diagnosis and management of patients with peripheral arterial diseases: a companion document of the 2017 ESC guidelines for the diagnosis and treatment of peripheral arterial diseases, in collaboration with the european society for vascular surgery (ESVS). Eur J Vasc Endovasc Surg 2018; 55(4): 457-64.
[http://dx.doi.org/10.1016/j.ejvs.2017.08.014] [PMID: 29628287]
[64]
Cohen AT, Hamilton M, Mitchell SA, et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS One 2015; 10(12): e0144856.
[http://dx.doi.org/10.1371/journal.pone.0144856] [PMID: 26716830]
[65]
Zalpour A, Oo TH. Update on edoxaban for the prevention and treatment of thromboembolism: clinical applications based on current evidence. Adv Hematol 2015; 2015: 920361.
[http://dx.doi.org/10.1155/2015/920361] [PMID: 26351456]
[66]
Weitz JI, Harenberg J. New developments in anticoagulants: Past, present and future. Thromb Haemost 2017; 117(7): 1283-8.
[http://dx.doi.org/10.1160/TH16-10-0807] [PMID: 28594426]
[67]
Perales IJ, San Agustin K, DeAngelo J, Campbell AM. Rivaroxaban versus warfarin for stroke prevention and venous thromboembolism treatment in extreme obesity and high body weight. Ann Pharmacother 2020; 54(4): 344-50.
[http://dx.doi.org/10.1177/1060028019886092] [PMID: 31672028]
[68]
Hanni C, Petrovitch E, Ali M, et al. Outcomes associated with apixaban vs warfarin in patients with renal dysfunction. Blood Adv 2020; 4(11): 2366-71.
[http://dx.doi.org/10.1182/bloodadvances.2019000972] [PMID: 32463871]
[69]
Nishimoto Y, Yamashita Y, Morimoto T, et al. Validation of the VTE-BLEED score’s long-term performance for major bleeding in patients with venous thromboembolisms: From the COMMAND VTE registry. J Thromb Haemost 2020; 18(3): 624-32.
[http://dx.doi.org/10.1111/jth.14691] [PMID: 31785073]
[70]
Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8(1): 202-4.
[http://dx.doi.org/10.1111/j.1538-7836.2009.03678.x] [PMID: 19878532]
[71]
van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124(12): 1968-75.
[http://dx.doi.org/10.1182/blood-2014-04-571232] [PMID: 24963045]
[72]
Drugs for treatment and prevention of venous thromboembolism. Med Lett Drugs Ther 2018; 60(1542): 41-8.
[PMID: 29537392]
[73]
Frenkel Rutenberg T, Velkes S, Vitenberg M, et al. Morbidity and mortality after fragility hip fracture surgery in patients receiving vitamin K antagonists and direct oral anticoagulants. Thromb Res 2018; 166: 106-12.
[http://dx.doi.org/10.1016/j.thromres.2018.04.022] [PMID: 29727737]
[74]
Petersen PB, Lindberg-Larsen M, Jørgensen CC, Kehlet H. Lundbeck foundation centre for fast-track H, knee arthroplasty collaborating g. Venous thromboembolism after fast-track elective revision hip and knee arthroplasty - A multicentre cohort study of 2814 unselected consecutive procedures. Thromb Res 2021; 199: 101-5.
[http://dx.doi.org/10.1016/j.thromres.2021.01.003] [PMID: 33485092]
[75]
Galanaud JP, Sevestre MA, Genty C, et al. Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis. J Thromb Haemost 2014; 12(4): 436-43.
[http://dx.doi.org/10.1111/jth.12512] [PMID: 24450376]
[76]
Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340(12): 901-7.
[http://dx.doi.org/10.1056/NEJM199903253401201] [PMID: 10089183]
[77]
Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368(8): 709-18.
[http://dx.doi.org/10.1056/NEJMoa1113697] [PMID: 23425163]
[78]
Schulman S, Granqvist S, Holmström M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336(6): 393-8.
[http://dx.doi.org/10.1056/NEJM199702063360601] [PMID: 9010144]
[79]
Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362(9383): 523-6.
[http://dx.doi.org/10.1016/S0140-6736(03)14111-6] [PMID: 12932383]
[80]
Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2018; 2(22): 3257-91.
[http://dx.doi.org/10.1182/bloodadvances.2018024893] [PMID: 30482765]
[81]
Mai V, Guay CA, Perreault L, et al. Extended anticoagulation for VTE: a systematic review and meta-analysis. Chest 2019; 155(6): 1199-216.
[http://dx.doi.org/10.1016/j.chest.2019.02.402] [PMID: 31174635]
[82]
Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369(9): 799-808.
[http://dx.doi.org/10.1056/NEJMoa1302507] [PMID: 23808982]
[83]
Büller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366(14): 1287-97.
[http://dx.doi.org/10.1056/NEJMoa1113572] [PMID: 22449293]
[84]
Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363(26): 2499-510.
[http://dx.doi.org/10.1056/NEJMoa1007903] [PMID: 21128814]
[85]
Lieberman JR, Heckmann N. Venous thromboembolism prophylaxis in total hip arthroplasty and total knee arthroplasty patients: from guidelines to practice. J Am Acad Orthop Surg 2017; 25(12): 789-98.
[http://dx.doi.org/10.5435/JAAOS-D-15-00760] [PMID: 29176502]
[86]
Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest . 2012; 141 (2 Suppl): e278S-325S.
[87]
Jacobs JJ, Mont MA, Bozic KJ, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am 2012; 94(8): 746-7.
[http://dx.doi.org/10.2106/JBJS.9408.ebo746] [PMID: 22517391]
[88]
Giuliano KK, Pozzar R, Hatch C. Thromboprophylaxis after hospitalization for joint replacement surgery. J Healthc Qual 2019; 41(6): 384-91.
[http://dx.doi.org/10.1097/JHQ.0000000000000204] [PMID: 31082932]
[89]
Vedovati MC, Giustozzi M, Becattini C. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants. Thromb Res 2019; 177: 33-41.
[http://dx.doi.org/10.1016/j.thromres.2019.02.031] [PMID: 30849513]
[90]
Levine MN, Gu C, Liebman HA, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 2012; 10(5): 807-14.
[http://dx.doi.org/10.1111/j.1538-7836.2012.04693.x] [PMID: 22409262]
[91]
Lee AYY. When can we stop anticoagulation in patients with cancer-associated thrombosis? Hematology (Am Soc Hematol Educ Program) 2017; 2017(1): 128-35.
[http://dx.doi.org/10.1182/asheducation-2017.1.128] [PMID: 29222247]
[92]
Sokol J, Nehaj F, Kubašková M, et al. Direct oral anticoagulants in oncology in clinical praxis. Vnitr Lek 2019; 65(1): 45-50.
[http://dx.doi.org/10.36290/vnl.2019.010] [PMID: 30823837]
[93]
Carrier M, Blais N, Crowther M, et al. Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus. Curr Oncol 2018; 25(5): 329-37.
[http://dx.doi.org/10.3747/co.25.4266] [PMID: 30464682]
[94]
Mahmoodi BK, Brouwer JL, Ten Kate MK, et al. A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. J Thromb Haemost 2010; 8(6): 1193-200.
[http://dx.doi.org/10.1111/j.1538-7836.2010.03840.x] [PMID: 20230415]
[95]
Rodger MA, Le Gal G, Anderson DR, et al. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ 2017; 356: j1065.
[http://dx.doi.org/10.1136/bmj.j1065] [PMID: 28314711]
[96]
Undas A, Goralczyk T. Non-vitamin K antagonist oral anticoagulants in patients with severe inherited thrombophilia: a series of 33 patients. Blood Coagul Fibrinolysis 2017; 28(6): 438-42.
[http://dx.doi.org/10.1097/MBC.0000000000000613] [PMID: 28079536]
[97]
Bereziuk OM, Mazur JV, Berko GK, et al. Primary and secondary thrombophilismall a, Cyrillic: Pathogenesis, clinical presentation, approaches to thrombotic complications prevention and treatment. Wiad Lek 2019; 72(5 cz 1): 908-13.
[98]
Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179(5): 417-26.
[http://dx.doi.org/10.1503/cmaj.080493] [PMID: 18725614]
[99]
Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132(13): 1365-71.
[http://dx.doi.org/10.1182/blood-2018-04-848333] [PMID: 30002145]
[100]
Elsebaie MAT, van Es N, Langston A, Büller HR, Gaddh M. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis. J Thromb Haemost 2019; 17(4): 645-56.
[http://dx.doi.org/10.1111/jth.14398] [PMID: 30690830]
[101]
Pinjala RK, Reddy LR, Nihar RP, Praveen GV, Sandeep M. Thrombophilia - how far and how much to investigate? Indian J Surg 2012; 74(2): 157-62.
[http://dx.doi.org/10.1007/s12262-011-0407-2] [PMID: 23542761]
[102]
Margetic S. Diagnostic algorithm for thrombophilia screening. Clin Chem Lab Med 2010; 48(Suppl. 1): S27-39.
[http://dx.doi.org/10.1515/CCLM.2010.362] [PMID: 21054193]
[103]
Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med 2008; 359(19): 2025-33.
[http://dx.doi.org/10.1056/NEJMra0707993] [PMID: 18987370]

Rights & Permissions Print Cite
Article Metrics
40
4
© 2024 Bentham Science Publishers | Privacy Policy